research use only
Cat.No.E0245
|
In vitro |
DMSO
: 33 mg/mL
(201.02 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 164.16 | Formula | C6H12O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 3615-41-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | L-Rhamnose | Smiles | CC(O)C(O)C(O)C(O)C=O | ||
| In vitro |
The polymeric copies of a rhamnose motif form glycopolymers (ARGPs), which can bind endogenous antirhamnose antibodies present in human serum, thus attract antibodies from human serum to the target cell surface. |
|---|---|
| In vivo |
Rhamnose(Rha) conjugated immunogens induces high titers of anti-Rha antibodies in wildtype mice, which can replace α1,3galactosyltransferase knockout (α1,3GT KO) mice in such antigen/antibody-mediated vaccine design when developing cancer immunotherapies. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06392360 | Recruiting | Metabolic Disturbance|Permeability; Increased |
Appalachian State University|AGRANA |
May 13 2024 | Not Applicable |
| NCT05999708 | Withdrawn | Colitis Ulcerative |
GlaxoSmithKline |
October 31 2023 | Phase 1 |
| NCT04109352 | Unknown status | Glucose-Galactose Malabsorption|Enteropathy|Malnutrition Child|Intestinal Permeability|Linear Growth Failure |
University of Virginia|International Atomic Energy Agency|Flinders University|International Centre for Diarrhoeal Disease Research Bangladesh|St. John''s Research Institute|The University of The West Indies|Mmust Masinde Muliro University of Science and Technology|Asociacion Benefica Prisma|Scottish Universities Environmental Research Centre|University of Michigan|Tropical Diseases Research Centre Zambia|Gastroenterology Services Ltd. |
September 1 2019 | -- |
| NCT03986476 | Completed | IBS |
Örebro University Sweden |
March 26 2019 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.